Who are Taltz's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bimzelx, Cosentyx, Subcutaneous injection of Secukinumab, Cosentyx, BIMZELX.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/taltz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Taltz — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Taltz (Taltz) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Interleukin-17A Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Taltz (Taltz) — Yale University.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Taltz TARGET	Taltz	Yale University	marketed		Interleukin-17A
Bimzelx	BIMEKIZUMAB	Ucb Japan Co., Ltd.	marketed		Interleukin-17A	2021-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)
Cosentyx	Cosentyx	Janssen Research & Development, LLC	marketed		Interleukin-17A
BIMZELX	BIMEKIZUMAB-BKZX	UCB INC	marketed		Interleukin-17A, Interleukin-17F, Interleukin-17AF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Taltz — Competitive Intelligence Brief. https://druglandscape.com/ci/taltz. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing